For the first time in 185 years UriahCatalan family pharmaceutical company decided to enter the sector British ICG fund With about 30 percent of people capital increase. The company also achieved one of its goals: to acquire the French company. ineldeaIt represents the largest acquisition in history.
The entry of a partner whose financial contribution is not disclosed, as one of the major Catalan pharmaceutical companies has already done SteveIt will be strengthened by the German private investment company Lubea’s acquisition of 26 percent of the capital of Esteve Healthcare, not brands like Isdin. Uriach’s strategy to cement itself as a leader in the ‘natural health’ business. Chairman of the property owners’ council, Enrique Uriach; chairman of the board, monetary Lluís Cantarell; and CEO, Oriol Segarra; We presented these new milestones of the company
Uriach had already predicted last June that his goal was: Entry into the French market made the largest acquisition in its history. Ineldea, which has a history of approximately 20 years, has an annual turnover of nearly 100 million.
500 million
The company had been planning this type of operation for more than three years. With the new step, the company’s sales figure is expected to reach 450 million in 2025, and does not ignore reaching 500 million by foreseeing these targets.
Segarra explained that with the entry of the fund, they will be able to accelerate growth and strengthen themselves in the countries where they are already present, such as in Italy, where other acquisitions were made after the first acquisition.
Enrique Uriach assured that these moves will consolidate the company’s transformation from “a small local family business to a multinational company”.
“We continue to work to grow in Europe, our target market is France and it is the last of the major markets we have left to complement our European platform,” Segarra said.
The company’s target in 2021 pharmaceutical department and factories Only in the Barcelona towns of Sant Fost de Campsentelles and Palau-solità i Plegamans natural partis to strengthen itself in Europe. In the year it got rid of the traditional medicine business, it acquired the German company Sidroga.
Controlled by Uriach fifth generation familyIt completed 2022, the first year of its new phase, with a revenue of 272 million euros from the sale of pharmacy products of natural origin and over-the-counter products, known solely as the Natural Consumption Healthcare (NCHC).